{"entity":{"id":"ddr2","kind":"target","name":"DDR2 receptor kinase","aka":[],"tldr":"DDR2 is a receptor that senses collagen; mutations in it occur in a small share of squamous lung cancers, and dasatinib inhibits it.","summary":"Discoidin domain receptor 2 is a receptor tyrosine kinase activated by fibrillar collagen rather than by a growth factor. DDR2 mutations were found in around 4 percent of squamous non-small cell lung cancers, and the leukaemia drug dasatinib inhibits DDR2 strongly, which prompted trials in DDR2-mutant lung cancer; responses were seen but the approach did not reach approval.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Discoidin_domain-containing_receptor_2","links":[{"label":"UniProt Q16832: DDR2","url":"https://www.uniprot.org/uniprotkb/Q16832/entry"},{"label":"HGNC:2731 DDR2","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2731"},{"label":"ChEMBL target CHEMBL5122","url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5122"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["dasatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"DDR2","role":[],"sources":[],"specificity":"broadly-expressed","distribution":"one-type","specificityNote":"Broadly expressed or essential: HPA finds the RNA at low tissue specificity; the 1 medicine aimed at it (Dasatinib) act on the wild-type protein, so normal tissue is exposed and the therapeutic window comes from the tumour's faster division or its dependence on the protein. HPA DDR2: RNA low tissue specificity; no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lung cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (colorectal cancer). (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas DDR2 tissue","url":"https://www.proteinatlas.org/ENSG00000162733-DDR2/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000162733 associations","url":"https://platform.opentargets.org/target/ENSG00000162733/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:2731","ensembl":"ENSG00000162733","uniprot":"Q16832","entrez":"4921","firstDescribed":1993,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Karn et al, Oncogene, 1993, \"Structure, expression and chromosomal mapping of TKT from man and mouse: a new subclass of receptor tyrosine kinases with a factor VIII-like domain\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/8247548/","biology":"Collagen binding through the discoidin domain triggers slow, sustained kinase activation, regulating cell adhesion, migration and matrix remodelling.","whereFound":["Squamous non-small cell lung cancer (a small mutated subset)","Fibroblasts and stromal cells"],"targetClass":"kinase","prevalence":[{"cancerId":"nsclc","pct":3.8,"measure":"DDR2 kinase mutation, Sanger sequencing of squamous cell lung cancers and cell lines","source":"https://doi.org/10.1158/2159-8274.CD-11-0005","note":"Squamous histology only; mutant cell lines and one patient responded to dasatinib"}]},"route":"/targets/ddr2/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/"}]}}